Asia News

Found 33,292 articles

• Carevature's Cutting-Edge Dreal® Technology Now Available to Spine Surgeons at Scripps Health

  8/20/2019

  Carevature Medical Inc. is pleased to announce that its unique Dreal® technology has been approved for use by neurosurgeons and orthopedic spine surgeons at Scripps Green Hospital in La Jolla, California.

• Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States

  8/20/2019

  Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced availability of the FDA-approved generic version of EpiPen Jr®1 (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S.

• Terason Partners With DiA Imaging Analysis to Bring Superior AI Cardiac Solutions to Point-of-care Ultrasound

  8/20/2019

  DiA's AI-based automated cardiac analysis solutions integrated in Terason's portable ultrasound devices

• Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Powder for Oral Solution, USP in the U.S. Market

  8/20/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Vigabatrin Powder for Oral Solution, USP in 500 mg per packet, a therapeutic equivalent generic version of Sabril® (vigabatrin) Powder for Oral Solution, USP, approved by the U.S. Food and Drug Administration (USFDA).

• CStone submits an abstract on CS1001-201 trial to 2019 ASH Annual Meeting

  8/20/2019

  CStone Pharmaceuticals announced that an abstract on the company's CS1001-201 trial has been submitted to the upcoming 2019 American Society of Hematology Annual Meeting.

• WuXi Biologics Reports Outstanding Interim Results

  8/19/2019

  WuXi Biologics (Cayman) Inc. announced its unaudited interim results for the six months ended June 30, 2019.

• NUS, Agilent, and NUH Launch New Translational R&D Hub to Boost Clinical Diagnostics

  8/19/2019

  The National University of Singapore (NUS), Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, and National University Hospital (NUH), have established Singapore’s first integrated translational R&D hub that leverages biochemical innovation and research data analytics to develop new methods of translating clinical research into clinical diagnostics.

• Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare

  8/19/2019

  GE Healthcare facility in Chicago to support clinical investigation needs of the C-Scan® System in the U.S.

• China SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019

  8/19/2019

  China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), today announced that its Annual Report on From 20-F for the fiscal year ended March 31, 2019

• Dr. Reddy's Laboratories announces the launch of Versavo® (bevacizumab biosimilar) in India

  8/19/2019

  Dr. Reddy’s Laboratories Ltd. announced that it has launched Versavo®, a biosimilar of Roche’s Avastin® in India, indicated for the treatment of several types of cancers.

• Abstract on CStone's CS1001-101 trial accepted for poster presentation at ESMO 2019 Annual Congress

  8/19/2019

  CStone Pharmaceuticals announced that an abstract on the company's ongoing CS1001-101 Phase Ib clinical study has been accepted for poster presentation at the upcoming European Society for Medical Oncology 2019 Annual Congress.

• Xylonix signs MOU with Biogemex to co-develop a predictive Cancer Immunotherapy Treatment Response Diagnostic

  8/16/2019

  Xylonix announced it has signed a Memorandum of Understanding (MOU) with BioGemex to jointly develop a new pre-treatment point-of-care diagnostic, XDX-01, to better predict a patient’s response to T-cell mediated cancer immunotherapies in solid tumors.

• Sinovac Reports Unaudited Second Quarter 2019 Financial Results

  8/15/2019

  Unaudited financial results for the second quarter ended June 30, 2019.

• 111, Inc. Launches New Video Interview Series on China's Healthcare Landscape

  8/15/2019

  111 Insight will focus on hot topics in the healthcare industry through interviews with industry experts, investors, and healthcare professionals.

• V-Wave's Interatrial Shunt Receives FDA Breakthrough Device Designation for Heart Failure

  8/15/2019

  V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has just granted the company a Breakthrough Device Designation for its interatrial shunt for Heart Failure (HF).

• Novasec Funds the Future with New Renewable Energy Investment Platform

  8/15/2019

  Novasec’s platform combines the renewable energy sector with digital securities, providing investors the potential for lower-risk, competitive returns.

• Estar Medical: Regenlab is in Breach of UK Court Orders Following Revocation of its PRP Patent

  8/15/2019

  Regen Lab SA (Regenlab) has failed to pay legal costs ordered by the UK High Court after revocation of its PRP patent for lack of novelty and inventive step. Regenlab is exposed to enforcement procedures which may limit its ability to provide products in the marketplace

• Ping An Reports Steady Growth of 23.8% in Operating Profit Attributable to Shareholders of the Parent Company in 1H 2019

  8/15/2019

  Ping An Continuously Improves Shareholder Returns with Cash Dividend and Share Repurchase Totaling RMB17.1 Billion in 1H 2019

• DarioHealth Announces Alliance with DigitalHealth.London As Part of the UK Israel Dangoor Health Initiative

  8/15/2019

  DarioHealth Corp. ("DarioHealth" or "Dario") (Nasdaq: DRIO), a leading, global digital therapeutics company, today announced an alliance with DigitalHealth.London ("DH.L") as part of its UK Israel Dangoor Health Initiative (the "Initiative"), which aims to partner leading Israeli digital health companies with the UK National Health Service (NHS) to benefit patients.

• CStone Pharmaceuticals Reports First Half 2019 Financial Results

  8/15/2019

  CStone Pharmaceuticals, a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and molecularly-targeted drugs for the treatment of cancer, released its recent business highlights and financial results for the first half of 2019.